Altavant Sciences is a clinical stage biopharmaceutical company formed to advance promising therapies in areas of high unmet medical need with an initial therapeutic focus in pulmonary arterial hypertension.

Altavant’s lead candidate is rodatristat ethyl*, a tryptophan hydroxylase (TPH) inhibitor. TPH inhibitors reduce the body’s peripheral production of serotonin, lowering circulating serotonin levels in diseases characterized by excessive production of the neurotransmitter, including pulmonary arterial hypertension (PAH), certain types of cancer, GI disorders, fibrosis and inflammation. Rodatristat ethyl is currently preparing for Phase 2 clinical development for pulmonary arterial hypertension with a number of additional indications being explored.

The Altavant team is passionate about building a culture that celebrates new ideas and persistence, with a deep commitment to pursue scientific innovation and novel approaches to drug development. We believe that in doing so, we can most effectively impact patients’ lives.

*name applied for; application pending


Bill Symonds, PharmD
Chief Executive Officer
Bill Symonds has served as the chief executive officer of Altavant Sciences since August 2018. Prior to joining Altavant, Dr. Symonds served as chief development officer of Roivant Sciences, Inc. since November 2016. He previously served as Roivant’s senior vice president, clinical research from the company’s inception in 2014 through November 2016.
From February 2012 to April 2014, Dr. Symonds served as vice president, liver disease therapeutic area at Gilead Sciences, Inc., and he was the senior vice president, clinical pharmacology and translational medicine, at Pharmasset, Inc. from 2007 to January 2012. From 1993 to 2007, Dr. Symonds held various positions of increasing responsibility at GlaxoSmithKline, most recently as director, antiviral clinical pharmacology and discovery medicine. Dr. Symonds received his Doctor of Pharmacy degree from Campbell University and completed a fellowship in clinical pharmacokinetics at the Clinical Pharmacokinetics Laboratory in Buffalo, New York.
↓ Read More
Lyn Baranowski
Chief Operating Officer
Lyn Baranowski joined Altavant with 15+ years of experience spanning biotech, big pharma and venture capital firms. She has significant experience leading commercial, transactional, financing and strategic functions as well as cross-functional teams across a diversity of product portfolios and therapeutic areas.
Prior to Altavant, she served as senior vice president, corporate development & strategy at Melinta Therapeutics, Inc. where she helped guide the company through many corporate milestones including FDA approval of the company’s lead drug, a successful corporate public listing, and an acquisition of a key business unit from the Medicines Company. Prior to that role, Ms. Baranowski served as vice president of commercial development at Pearl Therapeutics which successfully developed a portfolio of COPD drugs prior to its sale to AstraZeneca for $1.15 Billion in 2013. She also worked as vice president of Vatera Healthcare, a healthcare-focused private equity / venture capital firm based in New York, and in a variety of business development, marketing and public affairs / policy roles with Novartis Pharmaceuticals. She has an MBA from Harvard Business School and a BA from American University.
↓ Read More
Larry Keller, MD
VP, Clinical Development
Larry Keller has served as vice president, clinical development at Altavant since August 2018. He joined Altavant from IQVIA where he was vice president, global strategic drug development and head of the Cardiovascular Center of Excellence. Prior to IQVIA he held leadership positions in clinical R&D, medical affairs, established products, and regulatory strategy in companies including Pfizer, Kos Pharmaceuticals, Aldagen, and GlaxoSmithKline.
He has focused on cardiovascular drug development and has experience in several other therapeutic areas including rare diseases such as pulmonary arterial hypertension among others. Dr. Keller received his M.D. from The George Washington University and an M.S. in physiology from Georgetown University. He completed an internship and residency in pediatrics at The New York Hospital-Cornell Medical Center and a fellowship in pediatric cardiology at Children’s Hospital of Michigan. He became board-certified in pediatrics and pediatric cardiology and is a fellow of the American College of Cardiology.
↓ Read More
James Bishop
VP, Strategic Development and Business Operations
Jim Bishop is vice president, strategic development and business operations at Altavant Sciences, Inc. Previously, he served in chief of staff roles at Altavant Sciences and Roivant Sciences. He joined Roivant in February 2017 from Teva Pharmaceuticals where he was director, portfolio and operations management for the personalized and predictive medicines and big data analytics group.
In the roles prior to Teva, Jim was director of project management at Cabernet Pharmaceutical with a full-time consultant commitment to the Tailored Therapeutics group at Eli Lilly, he led the preclinical R&D efforts at Oxygen Biotherapeutics and was senior scientist in drug metabolism and pharmacokinetics at GlaxoSmithKline. He has an MBA from Meredith College and BS in biochemistry from Pennsylvania State University.
↓ Read More
Steve Wring, PhD
VP, Research and Development
Steve Wring joins Altavant Sciences from Roivant where he was the senior director, nonclinical drug disposition and modeling. Previously, he was the director of drug metabolism and pharmacokinetics for SCYNEXIS, Inc., with responsibility for advancing new drug-like molecules from early hits through lead optimization to candidate selection for human and animal health indications.
Prior to joining SCYNEXIS in 2007, Dr. Wring was principal investigator of DMPK at Trimeris Inc., where he led the DMPK optimization of synthetic peptide and small molecule fusion inhibitors of HIV infection. Before joining Trimeris in 2002, he gained 11 years discovery and development experience with GSK, both in the UK and USA. Dr. Wring received his PhD in analytical chemistry from the University of the West of England (Bristol, England) and has professional qualifications in clinical biochemistry and an MSc in instrumental analysis.
↓ Read More

Board of Directors

Myrtle Potter

Myrtle Potter was appointed Vant Operating Chair for Roivant Pharma in July 2018. In this role, she is expected to serve as one of two Roivant representatives on the boards of biopharmaceutical companies in the Roivant family.

Ms. Potter previously served as President and Chief Operating Officer of Genentech during a pivotal period of the company’s growth. Under her leadership, Genentech achieved record sales and earnings growth each year.

Prior to Genentech she was president of Bristol-Myers Squibb’s U.S. Cardiovascular and Metabolic business. She is a graduate of the University of Chicago and serves on the university’s board of trustees. She also serves on the boards of Rite Aid and Liberty Mutual Insurance Group, and previously served on the boards of Amazon, Express Scripts, and Medco Health Solutions.
↓ Read More
Frank Torti
>Dr. Torti joined Roivant in August 2018 from New Enterprise Associates (NEA), a leading venture capital firm where he served as partner. At NEA, Dr. Torti managed early and growth-stage investments in numerous healthcare companies that were responsible for the development and commercialization of new drugs and medical devices important to clinical medicine today.
Prior to joining NEA in 2007, Dr. Torti was a researcher at the Duke University Center for Clinical & Genetic Economics. Dr. Torti received his M.D. from the University of North Carolina School of Medicine and his M.B.A. with distinction from Harvard Business School.
↓ Read More